阿拉丁(688179) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 130,180,313.51, representing a year-on-year increase of 32.20% compared to CNY 98,473,575.99 in the same period last year[4] - Net profit attributable to shareholders for the same period was CNY 24,182,495.49, up 41.35% from CNY 17,107,659.32 year-on-year[4] - Basic earnings per share rose by 50.00% to CNY 0.09 from CNY 0.06 in the previous year[5] - The company reported a diluted earnings per share of CNY 0.09, consistent with the basic earnings per share, indicating a 50.00% increase year-on-year[5] - Operating profit for Q1 2025 was ¥34,048,976.46, an increase of 74.5% from ¥19,518,862.64 in Q1 2024[19] - The company reported a total comprehensive income of ¥24,281,491.76 for Q1 2025, compared to ¥17,129,834.75 in Q1 2024[20] Cash Flow - The net cash flow from operating activities increased significantly by 130.14%, reaching CNY 33,690,148.03 compared to CNY 14,638,706.12 in the previous year[4] - Cash flow from operating activities for Q1 2025 was ¥33,690,148.03, compared to ¥14,638,706.12 in Q1 2024, indicating a significant improvement[21] - Cash flow from investing activities for Q1 2025 showed a net outflow of ¥41,285,281.53, worsening from a net outflow of ¥22,909,560.12 in Q1 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,812,575,716.34, reflecting a 1.92% increase from CNY 1,778,424,528.59 at the end of the previous year[5] - The company's cash and cash equivalents decreased to RMB 421,402,808.68 from RMB 466,796,211.45, reflecting a decline of approximately 9.7%[15] - The total liabilities increased to RMB 659,013,937.99 from RMB 635,252,622.94, representing an increase of about 3.5%[17] - The company's equity attributable to shareholders rose slightly to RMB 1,071,043,938.29 from RMB 1,066,069,573.61, indicating a growth of approximately 0.5%[17] Research and Development - Research and development expenses totaled CNY 17,718,759.55, which is 13.61% of operating revenue, a slight decrease from 14.31% in the previous year[5] - The company experienced a significant increase in research and development expenses, which rose to ¥17,718,759.55 in Q1 2025 from ¥14,095,847.62 in Q1 2024[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,149[9] Investments - The company plans to invest RMB 4,117 million in Shanghai Yamei Biopharmaceutical Technology Co., acquiring a 25% stake[12][13] Inventory and Payables - The company's inventory increased to RMB 536,726,674.45 from RMB 528,264,759.16, showing a growth of about 1.7%[15] - The company's accounts payable rose to RMB 60,214,626.29 from RMB 43,991,332.27, marking an increase of approximately 37%[16] - The company's long-term investments increased to RMB 2,517,744.99 from RMB 2,450,253.26, reflecting a growth of about 2.8%[16] Borrowings - The company reported a decrease in short-term borrowings to RMB 31,487,321.64 from RMB 31,435,162.10, indicating a slight reduction[16]